Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two small molecule drugs, pindolol and trazodone. Pindolol is a non-selective beta-adrenergic receptor blocker (beta blocker) primarily used to manage hypertension and angina. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) antidepressant, mainly indicated for major depressive disorder. The combination has been studied in the treatment of major depression, including treatment-resistant depression, where pindolol may enhance the antidepressant effect of trazodone by antagonizing presynaptic serotonin 5-HT1A autoreceptors, potentially accelerating or augmenting serotonergic antidepressant response[1][6]. This combination is not marketed as a fixed-dose product but has been investigated in clinical research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pindolol + trazodone.